To Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ)

NCT03622008 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Antibiotics Causing Adverse Effects in Therapeutic Use

Interventions

DRUG: FEP-TAZ 4 g
OTHER: Placebo

Sponsor

Wockhardt

Collaborators

[object Object]